Clinical trial
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and…
NCT00172107 · Shire, Industry · Completed
Key facts
| NCT number | NCT00172107 |
|---|---|
| Title | A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis |
| Official title | A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11 |
| Enrollment | 217 |
| Start date | May 18, 1995 |
| Primary completion | Mar 24, 1997 |
| Completion | Mar 24, 1997 |
| First posted | Sep 15, 2005 |
| Last update posted | May 17, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: